MedPath

Etodolac

Generic Name
Etodolac
Brand Names
Lodine
Drug Type
Small Molecule
Chemical Formula
C17H21NO3
CAS Number
41340-25-4
Unique Ingredient Identifier
2M36281008
Background

Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.

Indication

For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.

Associated Conditions
Acute Pain, Chronic Back Pain, Extra-Articular Rheumatism, Juvenile Idiopathic Arthritis (JIA), Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Rheumatoid Arthritis, Spinal Disorders
Clinical Trials
Related News

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Not Applicable
Recruiting
Conditions
Stage III Ovary Cancer
Ovarian Carcinoma
Fallopian Tube Cancer
Ovarian Cancer
Stage III Ovarian Cancer
Stage IV Ovarian Cancer
Stage II Fallopian Tube Cancer
Stage III Fallopian Tube Cancer
Stage II Ovary Cancer
Stage IV Ovary Cancer
Interventions
Behavioral: Mind-body resilience training
Behavioral: Music therapy
First Posted Date
2022-06-24
Last Posted Date
2025-05-18
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
35
Registration Number
NCT05429970
Locations
🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

and more 4 locations

Evaluation of the Effects of Treatments Applied to Patients With Facial Myalgia on Occlusion Parameters

Not Applicable
Completed
Conditions
Occlusion
Quality of Life
Interventions
First Posted Date
2022-03-02
Last Posted Date
2022-03-02
Lead Sponsor
Yuzuncu Yıl University
Target Recruit Count
60
Registration Number
NCT05261971
Locations
🇹🇷

Beyza Ünalan Değirmenci, Van, Turkey

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

Phase 3
Terminated
Conditions
Pain, Acute
Interventions
Drug: Fixed Dose Combination
First Posted Date
2017-04-25
Last Posted Date
2023-02-09
Lead Sponsor
Apsen Farmaceutica S.A.
Target Recruit Count
140
Registration Number
NCT03127592
Locations
🇧🇷

Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil

Etodolac and Post-bleaching Sensitivity

Phase 4
Completed
Conditions
Medicaments Substances in Therapeutic Use
Interventions
Drug: Placebo
First Posted Date
2016-08-29
Last Posted Date
2016-08-29
Lead Sponsor
Flavia Pardo Salata Nahsan
Target Recruit Count
50
Registration Number
NCT02881619

Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed Condition

First Posted Date
2013-04-15
Last Posted Date
2013-04-15
Lead Sponsor
IPCA Laboratories Ltd.
Target Recruit Count
36
Registration Number
NCT01831687
Locations
🇮🇳

Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India

Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fasting Condition

First Posted Date
2013-04-10
Last Posted Date
2013-04-10
Lead Sponsor
IPCA Laboratories Ltd.
Target Recruit Count
36
Registration Number
NCT01827865
Locations
🇮🇳

Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2012-12-13
Last Posted Date
2012-12-13
Lead Sponsor
IPCA Laboratories Ltd.
Target Recruit Count
36
Registration Number
NCT01749228
Locations
🇮🇳

Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition

Phase 1
Completed
Conditions
Fasting
Interventions
First Posted Date
2012-12-11
Last Posted Date
2012-12-11
Lead Sponsor
IPCA Laboratories Ltd.
Target Recruit Count
36
Registration Number
NCT01746719
Locations
🇮🇳

Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India

Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed Condition

First Posted Date
2012-11-28
Last Posted Date
2012-12-03
Lead Sponsor
IPCA Laboratories Ltd.
Target Recruit Count
36
Registration Number
NCT01735383
Locations
🇮🇳

Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India

Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fasting Condition

Phase 1
Completed
Conditions
Fasting
Interventions
First Posted Date
2012-11-28
Last Posted Date
2012-12-03
Lead Sponsor
IPCA Laboratories Ltd.
Target Recruit Count
36
Registration Number
NCT01735370
Locations
🇮🇳

Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy